Financial Ratios

SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

NSE : SPARCBSE : 532872ISIN CODE : INE232I01014Industry : Business SupportHouse : Sun Pharma
BSE301.15-15.85 (-5 %)
PREV CLOSE ( ) 317.00
OPEN PRICE ( ) 301.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 301.15 (67615)
VOLUME 11376
TODAY'S LOW / HIGH ( )301.15 301.15
52 WK LOW / HIGH ( )178.1 474
NSE300.15-15.8 (-5 %)
PREV CLOSE( ) 315.95
OPEN PRICE ( ) 300.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 300.15 (10019)
VOLUME 119875
TODAY'S LOW / HIGH( ) 300.15 300.15
52 WK LOW / HIGH ( )178.8 472.8
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-6.86-7.48-5.77-11.92-5.55
   CEPS(Rs)-6.50-7.11-5.35-11.56-5.26
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)15.80-7.47-6.42-0.7111.30
   Tax Rate(%)0.000.000.000.000.00
Margin Ratios
   Core EBITDA Margin(%)-89.65-136.07-53.36-403.58-82.73
   EBIT Margin(%)-90.02-138.48-55.54-403.22-79.48
   Pre Tax Margin(%)-93.22-148.19-59.75-406.70-79.53
   PAT Margin (%)-93.22-148.19-59.75-406.70-79.53
   Cash Profit Margin (%)-88.29-140.79-55.43-394.36-75.40
Performance Ratios
   ROA(%)-40.10-79.80-60.18-93.11-40.89
   ROE(%)-143.720.000.00-225.08-74.72
   ROCE(%)-69.44-225.57-254.10-178.95-59.95
   Asset Turnover(x)0.430.541.010.230.51
   Sales/Fixed Asset(x)1.711.071.960.712.48
   Working Capital/Sales(x)0.87-1.37-1.46-0.461.13
Efficiency Ratios
   Fixed Capital/Sales(x)0.580.930.511.400.40
   Receivable days46.2060.2524.2662.2827.67
   Inventory Days0.000.000.000.000.00
   Payable days
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-27.62-41.77-26.48-8.35-36.49
   Price/Book(x)11.36-39.75-22.07-135.6816.98
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)23.9259.3415.5533.7927.52
   EV/Core EBITDA(x)-28.11-45.27-30.37-8.64-36.52
   EV/EBIT(x)-26.57-42.85-28.01-8.38-34.63
   EV/CE(x)6.8829.0817.139.5212.63
   M Cap / Sales24.3958.8114.6832.9227.51
Growth Ratio
   Net Sales Growth(%)73.98-45.74229.31-57.99133.67
   Core EBITDA Growth(%)-12.94-38.8556.85-117.9142.03
   EBIT Growth(%)-13.09-35.2954.64-113.1126.18
   PAT Growth(%)-9.43-34.5851.62-114.8126.18
   EPS Growth(%)8.32-29.7151.62-114.8129.31
Financial Stability Ratios
   Total Debt/Equity(x)0.00-0.37-1.37-3.590.01
   Current Ratio(x)2.540.420.260.292.71
   Quick Ratio(x)2.540.420.260.292.71
   Interest Cover(x)-28.15-14.26-13.19-115.79-1547.78
   Total Debt/Mcap(x)0.010.060.030.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.